Brain Implants, AI Rivalry, and Identity Tokens Clash in 2026

A new brain implant for depression moves toward human trials

Motif Neurotech announced that its first-in-human study of a cortical implant targeting major depressive disorder will begin this month. The device delivers patterned electrical stimulation to a region of the prefrontal cortex that prior animal work linked to mood regulation. The company plans to enroll a dozen volunteers who have not responded to conventional medication. Participants will wear the implant for six months while clinicians record changes in depressive scores and neural activity. The trial marks a shift from the field’s usual focus on motor restoration. Most brain‑computer‑interface startups today build devices that let paralyzed users type or control a wheelchair. Motif’s pivot toward mental health reflects a broader belief that neuromodulation can address disorders that resist drug treatment. The move also raises ethical questions about altering mood through circuitry. Critics warn that commercial pressure could outpace safeguards.

China blocks Meta’s purchase of Manus amid a deepening AI standoff

China’s market regulator ordered the cancellation of Meta Platforms’ proposed acquisition of Manus, a Chinese AI startup specializing in large‑language‑model training. The decision arrived after weeks of diplomatic friction over export controls on advanced chips. Beijing framed the move as a defense of national security and a rebuke to what it calls “strategic asset stripping.” Meta’s bid, first reported earlier this year, would have given the social‑media giant a foothold in China’s fast‑growing generative‑AI market. The reversal underscores how U.S.‑China rivalry now reaches corporate deal‑making. Tech founders who once courted Chinese capital find their options shrinking. The Manus episode mirrors earlier clampdowns on chip sales and on foreign investment in semiconductor fabs. Companies that ignore the new reality risk losing access to both talent and data pipelines that fuel AI research.

US firms double down on Sam Altman’s World ID despite global backlash

A coalition of American technology firms announced financial backing for World ID, the iris‑based identity platform championed by Sam Altman. The backing came even as regulators in Europe and Asia issued warnings about privacy and biometric surveillance. World ID promises a universal, cryptographically secured identifier that can be used for online sign‑ups and payments. Supporters argue that a single, verifiable ID could reduce fraud and streamline onboarding for services ranging from dating apps to financial platforms. Detractors point to the risk of a de‑facto global biometric database. The debate echoes earlier controversies over facial‑recognition deployment in public spaces. Altman’s project now sits at the intersection of market ambition and civil‑rights advocacy.

Historical parallels: tech regulation, geopolitical tension, and societal impact

The current wave of friction recalls the 1996 Telecom Act, which opened the U.S. market to competition but also sparked a scramble for spectrum that later required antitrust intervention. Likewise, the 1973 oil shock forced governments to rethink energy dependence, prompting strategic reserves and fuel‑efficiency standards. Those crises reshaped policy frameworks and created new industry champions. In the early 2000s, the U.S. breakup of AT&T dismantled a monopoly and seeded a competitive broadband ecosystem. The decision was driven by concerns that a single network could stifle innovation and give the government excessive control over communications. Today’s AI rivalry and biometric‑ID push present a similar dilemma: how to balance national security, market dynamism, and individual rights. The brain‑implant field also bears a historical echo of the 1990s deep‑brain‑stimulation (DBS) rollout for Parkinson’s disease. Early adopters hailed DBS as a breakthrough, while ethicists warned of “mind‑hacking.” Decades later, DBS became a standard therapy, but only after rigorous trials and regulatory scrutiny. Motif’s upcoming study may follow a comparable path if outcomes prove robust.

What to watch next

Regulators in Beijing and Washington will soon publish guidelines that could shape the fate of the Meta‑Manus deal and future AI cross‑border investments. Investors should monitor the U.S. Committee on Foreign Investment’s next review cycle for signs of tighter controls. In the biometric arena, the European Data Protection Board is expected to release a draft ruling on World ID’s compliance with GDPR. Finally, the results of Motif Neurotech’s depression trial, slated for release in early 2027, will indicate whether neuromodulation can move from niche research to mainstream psychiatry. The convergence of these three stories will test how quickly policy can keep pace with rapid technological ambition.

Updates

• 2026-05-09 — The 19 Most Exciting Cars at the Beijing Auto Show 2026 (source)